Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
June 11, 2024
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a